Eduardo Rios

[Eduardo Rios @EdRiosg15]

@dr_yakupergun I think cross-over was not permitted in TB-02 as Dato-DXd was not approved in later lines in TNBC, but SG was already approved in third and beyond when designed.

Also in TB-02, some pts from control arm recieved other ADCs as subsequent therapies.

[OncoDaily @oncodaily]

Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo - Luis Antonio Lara Mejía (@LuisLara_M)

https://t.co/ehGHBE4WZo

#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #NSCLC

[Karla Centelles @KCentelles]

#SABCS24 Incredibly proud to be a mentee of the brilliant Mexican Oncologist doctor @anelcabrera , here she is presenting a @LACOG_group work on the interval between diagnosis and treatment of early breast cancer in Latin America.

[Oscar Arrieta @ogarrieta]

Entrega de reconocimiento @Incan al servicio de Mastografia del @incmnszmx por tener un alto estándar de calidad en la detección de cáncer de mama @DrJoseSifuentes @CCINSHAE_mx @SSalud_mx

[Oscar Arrieta @ogarrieta]

@LungPolicy The National Institute of Cancerology of Mexico @incanMX is present on the lung cancer screening map with DETECTO program @detectoincan @LungPolicy We want to expand screening to several cities in Mexico and LATAM @SMNYCT https://t.co/EUtK3Bivoy

[Luis Lara-Mejía @LuisLara_M]

📌Acompañanos este 1ro de diciembre a las 11:00 hrs en el @incanMX para presenciar la primera edición de ALKANZANDOTE🤲, evento informativo dirigido a pacientes con cáncer de pulmón y alteración ALK🧬

Habrá conexión vía zoom👇 https://t.co/n0bJIYV932

👉No te lo puedes perder!

[Eduardo Rios @EdRiosg15]

They found that co-occurring genetic alterations, including TP53 and CDKN2A/B loss, could impact treatment outcomes. Patients with CDKN2A/B loss had a significantly higher risk of brain metastasis and shorter survival.

Check the original article at:

https://t.co/qn5usS8Ab4

[Eduardo Rios @EdRiosg15]

Groundbreaking findings in #LungCancer #Research !

Recently @LuisLara_M, @ogarrieta, et al., conducted a study in 5 Latin American centers involving 116 patients with advanced ALK-LC.

Finding suggests that genetic coalterations like TP53 and CDKN2A/B loss are game-changers.